RCM
SPRO icon

RA Capital Management’s Spero Therapeutics SPRO Stock Holding History

RA Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-741,647
Closed -$10.9M – 28
2018
Q2 		$10.9M Hold
741,647
– – 0.71% 24
2018
Q1 		$10.6M Sell
741,647
-484,000
-39% -$5.87M 0.81% 22
2017
Q4 		$14.4M Buy
+1,225,647
New +$15M 1.21% 15

Other funds holding SPRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RA Capital Management's SPRO Position: Q3 2018 in Review

RA Capital Management sold out of Spero Therapeutics (SPRO) in Q3 2018, closing a stake of 741,647 shares — an estimated $10.9M sold.

RA Capital Management first reported a position in SPRO in Q4 2017 and held it in 3 quarters. The position peaked at $14.4M in Q4 2017. 53 funds tracked by Wall St. Rank hold SPRO as of Q3 2018.

  • RA Capital Management reported no remaining Spero Therapeutics position as of Q3 2018 after selling out during the quarter.
  • RA Capital Management sold 741,647 Spero Therapeutics shares in Q3 2018, an estimated $10.9M.
  • RA Capital Management first reported a position in Spero Therapeutics in Q4 2017 and held it in 3 quarters.
  • RA Capital Management's Spero Therapeutics position peaked at $14.4M in Q4 2017.
  • 53 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2018.

Based on RA Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.